Role of Perioperative Pentoxifylline on Liver Regeneration in Living Donor Liver Transplantation

After written informed consent, a pilot study will be conducted with 10 patients to assess for feasibility and drug safety following which the double-blinded randomized control trial (DB- RCT) will be carried out. For the DB- RCT, the patients will be randomized using computer generated randomization charts in to two groups: the Pentox group (Group I) and the Placebo group (Group C). The randomization and drug delivery will be done by independent personnel (Third party - not related to the study). The patients in the Pentox arm will receive Oral pentoxifylline 24 hours before LDLT at doses upto 15mg/kg in three divided doses and then continued till 7 days postoperatively. The control group will receive color-matched multivitamin tablets as placebo. Monitoring for drug related adverse events described according to the product monograph will be closely carried out. These include: cardiovascular system: Arrhythmias, unexplained tachycardia; Central nervous system: Dizziness, headache, somnolence; Gastrointestinal symptoms: Nausea, vomiting, heartburn, constipation.